Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the high prices of hair loss treatments, specifically cb-03-01 and KY19382. It also mentions the use of Minoxidil, finasteride, and RU58841.

Hair loss is linked to DHT, with treatments like finasteride and minoxidil being common but not definitive. Economic interests influence research, and there is potential for new treatments like PP405 and RU58841.

The conversation revolves around the experiences of different individuals with hair loss treatments like Minoxidil, Finasteride, and RU58841. The discussion includes various perspectives on the effects of these treatments, the importance of hair for self-esteem and attractiveness, and the influence of significant others on the decision to use or stop using these treatments.

A user is upset about hair loss due to seborrheic dermatitis and DUPA, which prevents a hair transplant. They mention using jojoba oil and discuss treatments like Minoxidil, finasteride, and RU58841.

Curly and wavy hair can make hair loss appear worse due to clumping, but using less product, shorter cuts, and leave-in conditioner can help manage appearance. Minoxidil and finasteride are considered for treatment, and some find that styling can hide thinning areas.

The user is experiencing hair loss and plans to use a treatment protocol including Saw Palmetto Berries, MCT Oil, Zinc, testosterone balancers, L-tyrosine, and L-theanine. They also use a specific dandruff shampoo and are open to non-prescription treatments.

User reports 12-week progress with HIMS spray, Minoxidil, micro-needling, and biotin. Notable baby hairs on crown and temples, hoping for further improvement.

A user shared their four-year experience using 0.5mg dutasteride and topical minoxidil once daily for aggressive early hair loss, maintaining their hairline and regrowing hair on the vertex. They've experienced positive social feedback and increased confidence but also deal with dry eyes from dutasteride and worry about its long-term effects and cost.

The user experienced significant hair shedding after long-term use of finasteride and dutasteride and is now considering trying RU58841 as a last resort. They have checked health factors and suspect stress and poor sleep may contribute to the shedding, but they are determined to try RU58841 to see if it helps with androgenetic alopecia.

The user is experiencing erectile dysfunction and emotional numbness, possibly due to using Dutasteride for hair loss, and is considering switching back to Finasteride. They are seeking advice on whether this change might resolve their symptoms.

The user has been using topical minoxidil, topical finasteride, microneedling, and ketoconazole shampoo for 9 months with positive results but is concerned about recent increased shedding. Another user advises that shedding is normal and suggests continuing the treatments consistently for up to a year to see solid results.

Hair loss treatments discussed include dutasteride and oral minoxidil. The conversation humorously compares male lions' manes to human balding.

The conversation discusses a user experimenting with RU58841 for hair regrowth by ingesting it, which others find concerning. There are mentions of potential side effects and comparisons to other treatments like minoxidil, finasteride, and flutamide.

The user has been using topical minoxidil and dutasteride but is experiencing significant hair shedding, including smaller hairs. They are concerned if this shedding indicates the treatment is working.

The conversation discusses hair loss treatments, including finasteride, microneedling, minoxidil, and PTD-DBM. The user has not noticed significant regrowth and is considering cost-effective options like valproic acid.

Scientists found hidden stem cells that might reactivate hair growth. The discussion includes treatments like Minoxidil, finasteride, and RU58841.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

The conversation discusses hair regrowth progress from Norwood scale 4 to 2.5 over a year using daily 8.5-9% RU58841, topical Dutasteride 0.1%, RU58841 5% 1.5 times a week, and daily caffeine redensyl scalp treatment.

The conversation discusses hair regrowth progress using topical dutasteride with cetirizine, laser therapy, and growth serum. The user observes miniaturized, vellus hairs on the scalp.

The conversation discusses using Bimatoprost for eyebrow regrowth and its potential use on the hairline, with concerns about cost and side effects. Alternatives like topical Minoxidil are mentioned, but the user is worried about aging and acne.

A user shared their experience with hair loss treatments, switching from 1mg finasteride and topical minoxidil to 5mg oral minoxidil and oral dutasteride, noting improvements despite shedding phases. Other users discussed the hair growth cycle, treatment effects, and shared advice on managing hair loss, including buzzing hair and maintaining mental health.

The conversation discusses various theories of hair loss, including DHT sensitivity and genetic factors, with the user willing to use themselves for research due to having a hair loss gene but different hair loss patterns compared to their brothers. Specific treatments were not mentioned in the provided text.

Stopping treatments like Minoxidil, Finasteride, or Dutasteride leads to hair loss reversal. Personal reasons, such as planning for a baby, can influence the decision to stop these treatments despite the known consequences.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

The conversation is about creating a higher concentration of the newly FDA-approved hair loss treatment, Clascoterone (Winlevi), through compounding pharmacies and possibly organizing group purchases. Some users are unfamiliar with Winlevi and are asking for an explanation of the drug.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.

A bald groom was beaten by the family of the bride for wearing a wig. The conversation discusses the cultural stigma around baldness in India and the consequences of deception in arranged marriages.

Various hair growth treatments were discussed, including microneedling, bimatoprost, setipiprant, stemoxydine, PGE2, CB-03-01, WNT Beta-Catenin upregulators, KY19382, topical estrogen, IGF-1, GH, MK-677, oral castor oil, fisetin, resveratrol, cetrizine, and lactic acid. Users shared experiences and sources for these treatments, with some expressing interest in topical solutions and others noting the lack of FDA approval or scientific evidence for certain options.

The user experienced hair loss since 2021, tried various treatments, and is currently using oral minoxidil and finasteride since December 2024. They are experiencing shedding, which is common when starting or stopping treatments, and are advised to continue the current regimen as it may stabilize over time.